Aiming for Global Top-Tier Status Through KOSDAQ Listing
GC Genome Secures Preliminary Approval,
Strengthens Position in Next-Generation Cancer Screening
GC Genome, a company specializing in liquid biopsy and clinical genomics, announced on March 27 that it has received preliminary approval for listing from the Korea Exchange.
GC Genome
GC Genome, a leading clinical genomics analysis company, was established in 2013 as a subsidiary of GC Green Cross. The company provides disease diagnosis and prediction, as well as customized treatment solutions. It has built a diverse service portfolio of more than 300 types of personalized genetic tests covering the entire life cycle, from prenatal to elderly stages. Its main services include health screening tests, prenatal and newborn tests, precision cancer diagnostics, and precision diagnostics for rare genetic diseases.
Its flagship products include 'G-NIPT,' an AI-based obstetric test, and 'iCansearch,' a multi-cancer early detection test. G-NIPT is a non-invasive prenatal screening test that has achieved the number one market share in domestic university hospitals due to its technological excellence. iCansearch can detect more than six types of cancers, including colorectal, lung, esophageal, liver, pancreatic and biliary tract, and ovarian cancers, using only 10 mL of blood.
GC Genome is known to have established a domestic sales network with over 900 hospitals and clinics, including 45 tertiary general hospitals. By leveraging the network of more than 5,000 hospitals and clinics operated by its group company GC Cell, it provides rapid specimen transport and services. In addition, the company is strengthening its presence in the global market through a global network with 38 companies in 19 countries, collaborating on research and development and technology exports.
Based on this collaborative network, GC Genome recorded an average annual sales growth rate of 21.5% over the past three years (2021-2023) and has maintained a gross profit margin of about 50%.
Last year, GC Genome received A and A ratings in the technical evaluation for its KOSDAQ listing. The funds raised through this listing will be used for 'research and development to expand cancer types and the full-cycle management of each cancer.'
Ki Changseok, CEO of GC Genome, stated, "Based on our proprietary liquid biopsy technology, GC Genome provides differentiated services such as the prenatal test 'G-NIPT' and the multi-cancer early screening test 'iCansearch.' Through this KOSDAQ listing, we aim to become a global top-tier player in next-generation cancer screening."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
